ICAAC 2012: Cobicistat-boosted Elvitegravir Does Not Interact with Methadone
- Details
- Category: HIV Treatment
- Published on Tuesday, 13 November 2012 00:00
- Written by Liz Highleyman
The new HIV integrase inhibitor elvitegravir, boosted with cobicistat, does not cause clinically important changes in levels of methadone or buprenorphine used to manage opiate addiction, researchers reported at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco.
ICAAC 2012: New Tenofovir Pro-drug Matches Potency of Original Version but with Less Toxicity
- Details
- Category: HIV Treatment
- Published on Tuesday, 06 November 2012 00:00
- Written by Liz Highleyman
Tenofovir alafenamide fumarate (TAF), the tenofovir pro-drug formerly known as GS-7340, has antiviral potency similar to that of tenofovir disoproxil fumarate (TDF), and a new "quad" formulation containing TAF works as well as the Stribild single-tablet regimen (elvitegravir/cobicistat/TDF/emtricitabine) but appears to be easier on the bones and kidneys, according to recently released data.
ICAAC 2012: Hepatitis C Can Be Successfully Treated in Injection Drugs Users with or without HIV
- Details
- Category: HCV Treatment
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
HIV negative and HIV positive chronic hepatitis patients in Vancouver with a history of injection drug use -- most of whom were on methadone maintenance -- achieved sustained response rates with interferon-based therapy similar to those of non-users, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. 
ICAAC 2012: Atazanavir Linked to Kidney Stones in People with HIV
- Details
- Category: HIV Treatment
- Published on Tuesday, 23 October 2012 00:00
- Written by Liz Highleyman
HIV positive people taking ritonavir-boosted atazanavir (Reyataz) are more likely to develop kidney stones than those using other antiretroviral medications, according to study data presented at the recent 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) in San Francisco and published in the November 1, 2012 issue of Clinical Infectious Diseases. Another study suggested that darunavir (Prezista) may also raise the risk.
ICAAC 2012: Simplified Abacavir/Atazanavir Combo Keeps HIV Suppressed, May Help Bones
- Details
- Category: Approved HIV Drugs
- Published on Wednesday, 10 October 2012 00:00
- Written by Liz Highleyman
Substituting abacavir/lamivudine (the drugs in Epzicom) for tenofovir/emtricitabine (the drugs in Truvada) and dropping the ritonavir (Norvir) booster with atazanavir (Reyataz) maintains undetectable HIV viral load and improves biomarkers of bone loss, researchers reported at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2012) last month in San Francisco. 
More Articles...
- ICAAC 2012: HIV May Be Shed in Semen Even If Blood Viral Load Is Undetectable
- ICAAC 2012: Bone Loss Is Common in French HIV Cohort, Linked to Older Age and Lower Weight
- ICAAC 2012: Infections are Common among HIV/HCV Coinfected Patients on Interferon
- ICAAC 2012: Novel NNRTI MK-1439 Shows Potent Activity, Distinct Resistance Profile
Web Design and Development by